Search results
The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens. For patients suspected of COVID-19 or asymptomatic indviduals, lab-comparable results in minutes.
Jun 26, 2020 · The new code is intended for use as the industry standard for accurate reporting and tracking of antigen tests using immunofluorescent or immunochromatographic technique for the detection of biomolecules produced by the SAR-CoV-2 virus.
Use of code 87635 will help to efficiently report and track testing services related to SARS-CoV-2 and will streamline the reporting and reim-bursement for this test in the United States.
- 260KB
- 4
Jul 6, 2020 · The American Medical Association (AMA) recently announced a new CPT code for reporting antigen testing of patients suspected of being infected with the novel coronavirus (SARS-CoV-2).
- Kent Moore
The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform. Intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from nasal swab and nasopharyngeal swab samples collected from individuals
Jun 25, 2020 · The new antigen test code is the latest update to the CPT code set since the CPT Editorial Panel expedited approval of new Category I codes to report molecular testing for the SARS-CoV-2 virus, and serological testing for COVID-19 antibodies.
The LumiraDx SAR-CoV-2 Ag Test is a single use fluorescence immunoassay device designed to detect the presence of the nucleocapsid protein antigen directly from SARS-CoV-2 in either...
